MORGAN STANLEY PLC/CALL/REVVITY/110/0.1/21.03.25 | Real-time Bid/Ask 11:59:35 31/05/2024 BST | ||
| 1.18 EUR / 1.31 EUR | +19.71% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
REVVITY, INC.
Latest news about REVVITY, INC.
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.18 | +13.46% |
| 30/05/24 | 1.04 | -12.61% |
| 29/05/24 | 1.19 | -17.93% |
| 28/05/24 | 1.45 | +5.84% |
| 27/05/24 | 1.37 | 0.00% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:00 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | REVVITY, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0ZPH |
| ISIN | DE000MG0ZPH7 |
| Date issued | 28/03/2024 |
| Strike | 110 $ |
| Maturity | 21/03/2025 (295 Days) |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.45 € |
|---|---|
| Lowest since issue | 0.88 € |
| Spread | 0.14 € |
| Spread % | 10.69% |
Company Profile
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows:
- medical diagnosis equipment (61%);
- analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc.
Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
Sector
-
Consensus: Revvity, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
108.3
USD
Average target price
123.7
USD
Spread / Average Target
+14.15%
- Stock Market
- Warrants
- Warrant
